Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00669
|
|||||
| Drug Name |
Clofazimine
|
|||||
| Synonyms |
(3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; B 663; B 663 (Pharmaceutical); B 663 (VAN); B 663, pharmaceutical; B-663; B. 663; CFZ; Chlofazimine; Clofazimina; Clofazimina [INN-Spanish]; Clofazimine (JAN/USP/INN); Clofazimine [USAN:INN:BAN]; Clofaziminum; Clofaziminum [INN-Latin]; G 30320; G-30,320; G-30320; Lampren; Lamprene; Lamprene (TN); Liposome-encapsulated clofazimine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; SMP2_000339
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Leprosy [ICD11: 1B20] | Approved | [1] | |||
| Therapeutic Class |
Antiinflammatory Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C27H22Cl2N4
|
|||||
| Canonical SMILES |
CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl
|
|||||
| InChI |
InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3
|
|||||
| InChIKey |
WDQPAMHFFCXSNU-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 2030-63-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 473.4 | Topological Polar Surface Area | 40 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
7.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321645
, 103400985
, 103755939
, 103914133
, 104153270
, 104301631
, 11112506
, 11466404
, 11467524
, 11486188
, 118816613
, 121269827
, 121363168
, 14761008
, 15356285
, 24714740
, 24893114
, 29221949
, 32963436
, 426821
, 4302579
, 46386952
, 46508174
, 47275676
, 47349472
, 47499671
, 47795160
, 48243512
, 48415799
, 49681815
, 49698463
, 50004010
, 50100467
, 50124245
, 50376246
, 56314325
, 57321463
, 602744
, 627688
, 7847344
, 7978968
, 8151803
, 855829
, 9132
, 92125497
, 92308020
, 92308564
, 93167165
, 93619701
, 96079551
|
|||||
| ChEBI ID |
CHEBI:3749
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Clofazimine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016 Jan;71(1):17-26. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.